ReviewFrontiers in immunology2026
Exploring microbial signatures in sarcoidosis: etiological and therapeutic implications of host-microbiota interactions.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a chronic inflammatory disease that can potentially affect any organ. From a pathogenetic standpoint, it is characterized by the formation of chronic granulomatous inflammation, which defines its histological hallmark. Unlike its pathogenetic mechanisms, the etiology of sarcoidosis remains poorly understood. Environmental triggers-such as viruses, bacteria, fungi, or exposure to damp environments-have been hypothesized as risk factors in genetically predisposed individuals. Recently, increasing attention has been given to the role of the gut microbiota in the development of various metabolic and autoimmune disorders. At this regard, the primary aim of this review has been to critically explore the potential role of the gut and lung microbiota in the onset of sarcoidosis. We examined current and available evidence regarding the composition of the pulmonary and intestinal microbiota in sarcoidosis, identifying possible differences compared to other interstitial lung diseases and trying to find potential correlations with the etiological and prognostic features of the disease. Furthermore, potential therapeutic implications for the treatment of sarcoidosis have been assessed, with a focus on the possibility of modulating the microbiota of affected individuals as a novel approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.